RT Journal Article
SR Electronic
T1 Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targets
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.30.23299247
DO 10.1101/2023.11.30.23299247
A1 Liu, Jun
A1 Hu, Sile
A1 Chen, Lingyan
A1 Daly, Charlotte
A1 Medina, Cesar Augusto Prada
A1 Richardson, Tom G
A1 Traylor, Matthew
A1 Dempster, Niall J
A1 Mbasu, Richard
A1 Monfeuga, Thomas
A1 Vujkovic, Marijana
A1 Tsao, Philip S
A1 Lynch, Julie A
A1 Voight, Benjamin F.
A1 Chang, Kyong-Mi
A1 VA Million Veteran Program
A1 Cobbold, Jeremy F
A1 Tomlinson, Jeremy W
A1 van Duijn, Cornelia M
A1 Howson, Joanna M M
YR 2023
UL http://medrxiv.org/content/early/2023/11/30/2023.11.30.23299247.abstract
AB BACKGROUND & AIMS Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 25% of the population and currently has no effective treatments. Plasma proteins with causal evidence may represent promising drug targets. We aimed to identify plasma proteins in the causal pathway of MASLD and explore their interaction with obesity.METHODS We analysed 2,941 plasma proteins in 43,978 European participants from UK Biobank. We performed genome-wide association study (GWAS) for all MASLD-associated proteins and created the largest MASLD GWAS (109,885 cases/1,014,923 controls). We performed Mendelian Randomization (MR) and integrated proteins and their encoding genes in MASLD ranges to identify candidate causal proteins. We then validated them through independent replication, exome sequencing, liver imaging, bulk and single-cell gene expression, liver biopsies, pathway, and phenome-wide data. We explored the role of obesity by MR and multivariable MR across proteins, body mass index, and MASLD.RESULTS We found 929 proteins associated with MASLD, reported five novel genetic loci associated with MASLD, and identified 17 candidate MASLD protein targets. We identified four novel targets for MASLD (CD33, GRHPR, HMOX2, and SCG3), provided protein evidence supporting roles of AHCY, FCGR2B, ORM1, and RBKS in MASLD, and validated nine previously known targets. We found that CD33, FCGR2B, ORM1, RBKS, and SCG3 mediated the association of obesity and MASLD, and HMOX2, ORM1, and RBKS had effect on MASLD independent of obesity.CONCLUSIONS This study identified new protein targets in the causal pathway of MASLD, providing new insights into the multi-omics architecture and pathophysiology of MASLD. These findings advise further therapeutic interventions for MASLD.Competing Interest StatementThe authors declare the following competing interests: S.H., L.C., C.D., C.A.P.M., M.T., R.M., T.M. and J.M.M.H. are full-time employees of Novo Nordisk. T.G.R. was part-time employee of Novo Nordisk during the project running. J.L. is supported by a University of Oxford Novo Nordisk Research Fellowship. N.D. was supported by a University of Oxford Novo Nordisk Research Training Fellowship. The remaining authors declare no competing interests.Funding StatementThis research is based on data from the MVP, Office of Research and Development, Veterans Health Administration and was supported by award MVP000 (mvp003/028b). MVP MASLD data was generated with Department of Veterans Affairs (VA) funding support (I01-BX003362: K.M.C., P.S.T., and M.V.) with additional support from resources and facilities of the VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457. This publication does not represent the views of the Department of Veterans Affairs or the United States Government. M.V. acknowledges support for this work from the National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases, grant R01 DK134575. J.L. is supported by a Novo Nordisk Postdoctoral Fellowship and N.D. through a Novo Nordisk clinical research training fellowship run in partnership with the University of Oxford. The work has been supported by the Medical Research Council (JWT) and by the Oxford NIHR Biomedical Research Centre (JWT).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided electronically signed informed consent. UK Biobank has approval from the North West Multi-centre Research Ethics Committee, the Patient Information Advisory Group, and the Community Health Index Advisory Group. The current study is a part of UK Biobank project 53639 and 65851.All participants gave full, informed, written consent for the liver biopsy (NHS research ethics reference: 17/WM/0130).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUK Biobank data are publicly available to bona fide researchers upon application at http://www.ukbiobank.ac.uk/using-the-resource/. Publicly available summary statistics are obtained from https://gwas.mrcieu.ac.uk/, https://www.ebi.ac.uk/gwas/, https://www.gtexportal.org/home/datasets, and https://pan.ukbb.broadinstitute.org. Bulk liver RNA-seq data are available in Gene Expression Omnibus (GEO) under accession GSE135251. SnRNA-seq and scRNA-seq data are available in GEO under accession GSE189175, GSE185477, GSE136103, GSE212837, GSE189600, and GSE192740. Other source of data or web source were clarified in the methods. Relevant detailed results generated in this study were presented in supplementary tables. Clinical data with respect to the liver biopsy samples were assessable through contacting J.W.T.MASLDmetabolic dysfunction-associated steatotic liver diseaseNAFLDnon-alcoholic fatty liver diseaseMASHmetabolic dysfunction-associated steatohepatitisNASHnon-alcoholic steatohepatitisMRMendelian randomizationMRI-PDFFmagnetic resonance imaging - estimated proton density fat fractionICDInternational Classification of DiseasesLC-MS/MSliquid chromatography-tandem mass spectrometryMSDMatrix Spectral DecompositionGWASgenome-wide association studyALTalanine aminotransferasePheMRphenome-wide Mendelian randomization studypQTLprotein quantitative trait locuseQTLexpression quantitative trait locusBMIbody mass indexVEPvariant effect predictorLOFTEEloss-of-function transcript effect estimatorDEGdifferentially expressed genessnRNA-seqsingle nucleus RNA sequencescRNA-seqsingle cell RNA sequenceage2age squaredSNPsingle-nucleotide polymorphismNAFLnon-alcoholic fatty liverGRHPRGlyoxylate and hydroxypyruvate reductaseHMOX2heme oxygenase 2HMOX1heme oxygenase 1IGFinsulin-like growth factorSCG3secretogranin IIIRBKSribokinaseORM1Orosomucoid 1AHCYadenosylhomocysteinaseFCGR2BFc gamma receptor IIb.